Abstract |
Clioquinol, a metal-binding compound, has been shown to have anticancer activity in in vitro and in vivo model systems. This study investigated the effects of clioquinol on cyclin D1 gene expression in breast cancer cells. Treatment with clioquinol significantly reduced cyclin D1 protein levels in a concentration-dependent manner, effects being more pronounced in the presence of zinc. Clioquinol reduced cyclin D1 mRNA contents in cells that had been pre-treated with actinomycin D, indicating that this compound alters cyclin D1 mRNA stability, an event associated with post-transcriptional regulation. Using a cyclin D1 3'-UTR reporter construct (CCND1-3'-UTR), we confirmed that this 3'-UTR mediates the inhibitory action of clioquinol, likely through miR-302C. This study demonstrates for the first time that clioquinol targets post-transcriptional steps of cyclin D1 gene expression in cancer cells, adding new insight into our understanding of its mechanisms of anticancer action.
|
Authors | Jie Zheng, Doris M Benbrook, Haijun Yu, Wei-Qun Ding |
Journal | Anticancer research
(Anticancer Res)
Vol. 31
Issue 9
Pg. 2739-47
(Sep 2011)
ISSN: 1791-7530 [Electronic] Greece |
PMID | 21868515
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 3' Untranslated Regions
- Antineoplastic Agents
- RNA, Messenger
- Cyclin D1
- Clioquinol
|
Topics |
- 3' Untranslated Regions
- Antineoplastic Agents
(pharmacology)
- Base Sequence
- Breast Neoplasms
(genetics, pathology)
- Cell Line, Tumor
- Clioquinol
(pharmacology)
- Cyclin D1
(genetics)
- Female
- Gene Expression
(drug effects)
- Humans
- Molecular Sequence Data
- Promoter Regions, Genetic
- RNA Processing, Post-Transcriptional
(drug effects)
- RNA, Messenger
(genetics)
- Transcription, Genetic
(drug effects)
|